Market research
APRE Aprea Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 3.55
- Dividend yield
- Not available
- Beta
- 1.59
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03836J2015
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 3.55
- Dividend yield
- Not available
- Beta
- 1.59
About
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the APRE discussion.
5 years, 4 months ago
Aprea Therapeutics, Inc is currently in a long term downtrend where the price is trading 54.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Aprea Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 17.7% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 25.7% to $-13M since the same quarter in the previous year.
Based on the above factors, Aprea Therapeutics, Inc gets an overall score of 1/5.